Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

IDIGH Calendar

<<  <  April 2019  >  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
  1  2  4  6  7
  8  9111314
151618192021
2223242528
2930     

Upcoming Events

Latest IDIGH Publications

  1. Saroli Palumbo, C., Bessissow, T. & Sebastiani, G.
    (2019)
    .
    Reply to "Transient Elastography in IBD Patients"
    .
    Inflammatory bowel diseases
  2. Fakih, I., Fortin, É., Smith, M.-A., Carignan, A., Tremblay, C., Villeneuve, J., Moisan, D., Frenette, C., Quach, C., Schmidt, A. M. & for SPIN-BACTOT.
    (2019)
    .
    Healthcare-associated bloodstream infection trends under a provincial surveillance program
    .
    Infection control and hospital epidemiology
    ,
    vol
    .
    40
    ,
    p
    .
    307-313
    .
  3. Rossi, C., Young, J., Martel-Laferrière, V., Walmsley, S., Cooper, C., Wong, A., Gill, M. J., Klein, M. B. & Canadian Co-Infection Cohort Investigators .
    (2019)
    .
    Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care
    .
    Open forum infectious diseases
    ,
    vol
    .
    6
    ,
    p
    .
    ofz055
    .
  4. Huang, J., Ma, Z., Zhong, G., Sheppard, D. C., Lu, L. & Zhang, S.
    (2019)
    .
    The mitochondrial thiamine pyrophosphate transporter TptA promotes adaptation to low iron conditions and virulence in fungal pathogen Aspergillus fumigatus
    .
    Virulence
  5. Mehraj, V., Ramendra, R., Isnard, S., Dupuy, F. P., Ponte, R., Chen, J., Kema, I., Jenabian, M.-A., Costiniuk, C., Lebouché, B., Thomas, R., Coté, P., Leblanc, R., Baril, J.-G., Durand, M., Chartrand-Lefebvre, C., Tremblay, C., Ancuta, P., Bernard, N. F., Sheppard, D. C., Routy, J.-P. & Montreal Primary HIV-infection Study and Canadian HIV and Aging Cohort Study Groups.
    (2019)
    .
    Circulating (1→3)-β-D-Glucan is associated with immune activation during HIV infection
    .
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
More publications